Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.63 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391611 | 0.86 | GPR119 (0.68) | GPR119CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL5201862 | 0.81 | GPR119 (0.70) | GPR119CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL3672449 | 0.79 | GPR119 (0.67) | GPR119CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL390760 | 0.79 | GPR119 (0.69) | GPR119CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL392046 | 0.79 | GPR119 (0.67) | GPR119CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL389458 | 0.77 | GPR119 (0.65) | GPR119KCNH2CYP3A4 | |
| SCHEMBL386244 | 0.77 | GPR119 (0.79) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL288892 | 0.77 | GPR119 (1.00) | GPR119KCNH2CYP2C9 | |
| SCHEMBL390833 | 0.77 | GPR119 (0.68) | GPR119CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL4719718 | 0.76 | GPR119 (0.79) | GPR119KCNH2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | GPR119, GLP1R, GPR4 | GPR119 1/4885CCNA2 4367/4885CDK2 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.